4//SEC Filing
LEFKOFF KYLE 4
Accession 0001209191-18-041857
CIK 0001100412other
Filed
Jul 5, 8:00 PM ET
Accepted
Jul 6, 4:06 PM ET
Size
13.1 KB
Accession
0001209191-18-041857
Insider Transaction Report
Form 4
LEFKOFF KYLE
Director
Transactions
- Exercise/Conversion
Common Stock
2018-07-06$5.95/sh+25,000$148,750→ 67,720 total - Sale
Common Stock
2018-07-06$17.45/sh−50,000$872,500→ 17,720 total - Exercise/Conversion
Common Stock
2018-07-06$5.13/sh+25,000$128,250→ 42,720 total - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-06−25,000→ 0 totalExercise: $5.13From: 2015-10-29Exp: 2024-10-29→ Common Stock (25,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2018-07-06−25,000→ 0 totalExercise: $5.95From: 2016-10-27Exp: 2025-10-27→ Common Stock (25,000 underlying)
Holdings
- 45,000(indirect: See footnote)
Common Stock
Footnotes (2)
- [F1]The price reported for these shares is the weighted average sale price of transactions made at prices from $17.45 to $17.461. Details of actual prices for shares sold are available from the Issuer upon request.
- [F2]Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.
Documents
Issuer
ARRAY BIOPHARMA INC
CIK 0001100412
Entity typeother
Related Parties
1- filerCIK 0001191818
Filing Metadata
- Form type
- 4
- Filed
- Jul 5, 8:00 PM ET
- Accepted
- Jul 6, 4:06 PM ET
- Size
- 13.1 KB